On April 30 2026, the FDA’s Oncology Drug Advisory Committee voted 3‑6 against recommending AstraZeneca’s experimental breast‑cancer drug camizestrant in combination with a CDK4/6 inhibitor for first‑line treatment of hormone‑receptor‑positive, HER2‑negative advanced breast cancer, while the same panel approved the company’s prostate‑cancer combination Truqap (capivasertib plus abiraterone and androgen‑deprivation therapy) with a 7‑1 vote.
Camizestrant’s Phase III SERENA‑6 trial reported a 56 % reduction in the risk of disease progression or death compared with standard care. Panel members expressed concerns that the trial’s design—switching treatment upon detection of an ESR1 mutation before radiographic progression—may not demonstrate a clinically meaningful benefit, and that overall survival data were still immature. These concerns led the committee to conclude that the evidence was insufficient to support a recommendation for the drug’s approval in this setting.
The positive vote for Truqap underscores AstraZeneca’s continued progress in its prostate‑cancer portfolio. The 7‑1 recommendation brings the combination closer to U.S. approval for PTEN‑deficient metastatic hormone‑sensitive prostate cancer, a subgroup with limited treatment options.
AstraZeneca’s Q1 2026 earnings, released on April 29 2026, showed earnings per share of $2.58 versus analyst expectations of $2.54, and revenue of $15.3 billion versus $14.9 billion. The oncology division contributed roughly 45 % of total revenue, and the company reiterated its 2030 revenue target of $80 billion while announcing continued investment in commercial operations and multiple drug launches to offset pricing pressure and patent losses.
Management comments highlighted the impact of the panel’s decision. Susan Galbraith, Executive Vice President of Oncology Haematology R&D, said, “New innovations and novel treatment strategies that provide benefit to patients are required to drive advances in this 1st‑line setting, and so we are disappointed with the mixed outcome of today’s ODAC meeting.” Investigator Kevin Kalinsky added, “Patients with this specific form of breast cancer are in urgent need of new treatments that delay disease progression. Today’s recommendation by the ODAC is disappointing, as new options and innovative treatment strategies which address emerging resistance ahead of disease progression and deterioration in quality of life are needed in the 1st‑line setting.” CEO Pascal Soriot noted, “Our strong performance in Q1 2026, particularly in oncology, underscores our commitment to delivering innovative medicines.” He also said, “The company remains ‘on track to achieve our ambition for 2030 and beyond,’ adding the firm was investing in its commercial operations and preparing multiple drug launches to offset pricing pressure and patent losses.”
The panel’s rejection of camizestrant represents a regulatory setback that could delay the drug’s market entry for this indication, while the approval of Truqap signals continued progress in AstraZeneca’s prostate‑cancer pipeline. Together, these outcomes illustrate the divergent paths of the company’s oncology portfolio and the importance of robust clinical evidence for regulatory approval.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.